Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACADNASDAQ:ASNDNASDAQ:IONSNASDAQ:SDGRNASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$20.88-0.3%$20.39$13.40▼$25.23$3.51B0.641.98 million shs2.02 million shsASNDAscendis Pharma A/S$175.98+1.0%$167.90$111.09▼$183.00$10.65B0.38501,562 shs476,887 shsIONSIonis Pharmaceuticals$41.78-2.8%$35.48$23.95▼$52.34$6.84B0.231.61 million shs2.24 million shsSDGRSchrodinger$20.63-2.3%$22.56$16.60▼$28.47$1.55B1.58914,907 shs928,245 shsUTHRUnited Therapeutics$290.39-1.4%$301.08$266.98▼$417.82$13.28B0.53446,457 shs649,708 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals-0.33%-3.20%-5.00%+48.09%+29.45%ASNDAscendis Pharma A/S+1.10%+1.96%+1.69%+28.07%+29.58%IONSIonis Pharmaceuticals-2.79%+5.75%+18.39%+63.78%-9.35%SDGRSchrodinger-1.57%+2.53%-16.21%+14.80%-0.39%UTHRUnited Therapeutics-1.42%+1.06%-10.87%+3.83%-7.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACADACADIA Pharmaceuticals4.6784 of 5 stars4.43.00.00.03.24.22.5ASNDAscendis Pharma A/S3.5704 of 5 stars4.53.00.00.02.51.70.6IONSIonis Pharmaceuticals4.6576 of 5 stars4.42.00.03.03.33.30.6SDGRSchrodinger2.7962 of 5 stars3.42.00.00.03.02.50.6UTHRUnited Therapeutics4.9946 of 5 stars4.35.00.04.63.03.32.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.71Moderate Buy$27.8833.50% UpsideASNDAscendis Pharma A/S 3.00Buy$220.6725.39% UpsideIONSIonis Pharmaceuticals 2.78Moderate Buy$58.2539.42% UpsideSDGRSchrodinger 2.75Moderate Buy$33.2561.17% UpsideUTHRUnited Therapeutics 2.69Moderate Buy$386.1532.98% UpsideCurrent Analyst Ratings BreakdownLatest ACAD, UTHR, SDGR, IONS, and ASND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025ASNDAscendis Pharma A/SMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$250.007/3/2025SDGRSchrodingerMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$28.007/1/2025IONSIonis PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$51.00 ➝ $57.006/30/2025UTHRUnited TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$410.00 ➝ $385.006/26/2025ACADACADIA PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform$19.00 ➝ $22.006/26/2025ACADACADIA PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$37.006/26/2025ACADACADIA PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.006/26/2025ACADACADIA PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.006/26/2025IONSIonis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/23/2025ACADACADIA PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$26.00 ➝ $38.006/13/2025ASNDAscendis Pharma A/SOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$215.00 ➝ $224.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$957.80M3.65$0.70 per share29.72$4.40 per share4.75ASNDAscendis Pharma A/S$393.54M27.34N/AN/A($1.88) per share-93.61IONSIonis Pharmaceuticals$705M9.43N/AN/A$3.73 per share11.20SDGRSchrodinger$207.54M7.29N/AN/A$5.78 per share3.57UTHRUnited Therapeutics$2.88B4.55$28.00 per share10.37$144.34 per share2.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$226.45M$1.3715.2427.474.5122.97%17.46%10.75%8/5/2025 (Estimated)ASNDAscendis Pharma A/S-$409.12M-$6.28N/A733.25N/A-93.22%N/A-33.29%9/2/2025 (Estimated)IONSIonis Pharmaceuticals-$453.90M-$2.99N/AN/AN/A-63.65%-91.85%-15.77%7/30/2025 (Estimated)SDGRSchrodinger-$187.12M-$2.63N/AN/AN/A-83.39%-44.74%-26.29%7/30/2025 (Estimated)UTHRUnited Therapeutics$1.20B$25.0611.5910.566.4540.44%19.33%16.73%7/30/2025 (Estimated)Latest ACAD, UTHR, SDGR, IONS, and ASND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025ACADACADIA Pharmaceuticals$0.14N/AN/AN/A$263.07 millionN/A7/30/2025Q2 2025SDGRSchrodinger-$0.83N/AN/AN/A$52.03 millionN/A7/30/2025Q2 2025UTHRUnited Therapeutics$6.89N/AN/AN/A$802.13 millionN/A5/7/2025Q1 2025ACADACADIA Pharmaceuticals$0.10$0.11+$0.01$0.11$239.32 million$244.32 million5/7/2025Q1 2025SDGRSchrodinger-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 million5/1/2025Q1 2025ASNDAscendis Pharma A/S-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 million4/30/2025Q1 2025IONSIonis Pharmaceuticals-$1.07-$0.93+$0.14-$0.93$144.31 million$132.00 million4/30/2025Q1 2025UTHRUnited Therapeutics$6.29$6.63+$0.34$6.63$726.82 million$794.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AASNDAscendis Pharma A/SN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.882.80ASNDAscendis Pharma A/SN/A1.040.71IONSIonis Pharmaceuticals2.639.669.62SDGRSchrodingerN/A3.453.45UTHRUnited TherapeuticsN/A5.465.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%ASNDAscendis Pharma A/SN/AIONSIonis Pharmaceuticals93.86%SDGRSchrodinger79.05%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals28.30%ASNDAscendis Pharma A/S40.00%IONSIonis Pharmaceuticals2.71%SDGRSchrodinger8.60%UTHRUnited Therapeutics10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510167.36 million120.00 millionOptionableASNDAscendis Pharma A/S1,01761.13 million36.68 millionOptionableIONSIonis Pharmaceuticals1,069159.16 million154.85 millionOptionableSDGRSchrodinger79073.38 million67.07 millionOptionableUTHRUnited Therapeutics1,30545.11 million40.46 millionOptionableACAD, UTHR, SDGR, IONS, and ASND HeadlinesRecent News About These CompaniesBrookstone Capital Management Makes New $1.48 Million Investment in United Therapeutics Corporation (NASDAQ:UTHR)July 7 at 5:06 AM | marketbeat.comWill United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?July 4, 2025 | zacks.comNew York State Teachers Retirement System Lowers Holdings in United Therapeutics Corporation (NASDAQ:UTHR)July 3, 2025 | marketbeat.comUnited Therapeutics Corporation (NASDAQ:UTHR) Holdings Raised by Sumitomo Mitsui Trust Group Inc.July 3, 2025 | marketbeat.comWhy Investors Need to Take Advantage of These 2 Medical Stocks NowJuly 2, 2025 | zacks.comAmalgamated Bank Trims Position in United Therapeutics Corporation (NASDAQ:UTHR)July 2, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Decreases Stock Holdings in United Therapeutics Corporation (NASDAQ:UTHR)July 2, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Sells 2,214 Shares of United Therapeutics Corporation (NASDAQ:UTHR)July 2, 2025 | marketbeat.comDiversified Trust Co Purchases 1,074 Shares of United Therapeutics Corporation (NASDAQ:UTHR)July 1, 2025 | marketbeat.comBessemer Group Inc. Cuts Stock Position in United Therapeutics Corporation (NASDAQ:UTHR)July 1, 2025 | marketbeat.comCambridge Investment Research Advisors Inc. Purchases 2,211 Shares of United Therapeutics Corporation (NASDAQ:UTHR)July 1, 2025 | marketbeat.comUBS Group Cuts United Therapeutics (NASDAQ:UTHR) Price Target to $385.00June 30, 2025 | marketbeat.comUnited Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for IPF TreatmentJune 30, 2025 | tipranks.comKBC Group NV Has $33.63 Million Position in United Therapeutics Corporation (NASDAQ:UTHR)June 30, 2025 | marketbeat.comPaul A. Mahon Sells 11,000 Shares of United Therapeutics Corporation (NASDAQ:UTHR) StockJune 29, 2025 | americanbankingnews.comUnited Therapeutics Corporation (UTHR) - Yahoo FinanceJune 28, 2025 | finance.yahoo.comUnited Therapeutics Corporation (NASDAQ:UTHR) EVP Paul A. Mahon Sells 11,000 SharesJune 28, 2025 | insidertrades.comUnited Therapeutics Announces World’s First Bioengineered External Liver Treatment in Clinical StudyJune 28, 2025 | msn.comUTHR United Therapeutics Corporation - Seeking AlphaJune 27, 2025 | seekingalpha.comInsider Selling: United Therapeutics Corporation (NASDAQ:UTHR) EVP Sells 11,000 Shares of StockJune 27, 2025 | marketbeat.comUnited Therapeutics Corporation (NASDAQ:UTHR) Shares Bought by Achmea Investment Management B.V.June 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendAST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!By Thomas Hughes | June 16, 2025View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!Analysts Supercharge AMD Stock Ahead of Q2 AI CatalystBy Thomas Hughes | June 26, 2025View Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst2 Under the Radar Space & Defense Stocks With Huge PotentialBy Leo Miller | July 1, 2025View 2 Under the Radar Space & Defense Stocks With Huge PotentialAs Oil Prices Rebound, These Stocks Could Fuel the Next RallyBy Sarah Horvath | June 9, 2025View As Oil Prices Rebound, These Stocks Could Fuel the Next RallyACAD, UTHR, SDGR, IONS, and ASND Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$20.88 -0.07 (-0.33%) As of 07/7/2025 04:00 PM EasternACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Ascendis Pharma A/S NASDAQ:ASND$175.98 +1.80 (+1.03%) As of 07/7/2025 04:00 PM EasternAscendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Ionis Pharmaceuticals NASDAQ:IONS$41.78 -1.22 (-2.84%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$41.78 0.00 (0.00%) As of 07/7/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.Schrodinger NASDAQ:SDGR$20.63 -0.49 (-2.32%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$20.52 -0.11 (-0.53%) As of 07/7/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.United Therapeutics NASDAQ:UTHR$290.39 -4.10 (-1.39%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$290.00 -0.39 (-0.13%) As of 07/7/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
